SCHEMBL3279484

SCHEMBL3279484

CCC(=O)C(N)c1c(C(=O)O)n(Cc2cccc3ccccc23)c2ccc(F)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.42
CYP2C9 P11712 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
PTGER2 P43116 2/20 0.41
POLB P06746 1/20 0.38
CMA1 P23946 1/20 0.38
PTGDR Q13258 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
PLA2G1B P04054 1/20 0.36
PLA2G2A P14555 1/20 0.36
TP53 P04637 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
PIK3C2B O00750 1/20 0.36
HASPIN Q8TF76 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283458 0.90 KMT2A (0.43) PTGDR2CYP2C9KMT2AMEN1PTGER2
SCHEMBL3275966 0.89 PTGDR2 (0.41) PTGDR2CYP2C9KMT2AMEN1PTGER2
SCHEMBL3275143 0.86 KMT2A (0.43) PTGDR2CYP2C9KMT2AMEN1PTGER2
SCHEMBL3276143 0.83 KMT2A (0.40) PTGDR2CYP2C9KMT2AMEN1POLB
SCHEMBL3276107 0.81 KMT2A (0.45) PTGDR2CYP2C9KMT2AMEN1PTGER2
SCHEMBL3283147 0.81 CRY1 (0.41) PTGDR2CYP2C9KMT2AMEN1PTGER2
SCHEMBL3276955 0.81 MEN1 (0.46) PTGDR2CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL3277663 0.81 KMT2A (0.48) PTGDR2CYP2C9KMT2AMEN1PTGER2
SCHEMBL3275876 0.80 MEN1 (0.46) PTGDR2KMT2AMEN1ALDH1A1MAPT
SCHEMBL3275935 0.79 KMT2A (0.46) PTGDR2CYP2C9KMT2AMEN1PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 PTGDR2 414/4885CYP2C9 741/4885KMT2A 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.